Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial

BACKGROUND: CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients randomized to intramuscular interferon beta-1a (IM IFN beta-1a), glatiramer acetate (GA), or both therapies. OBJECTIVE: This analysis investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cutter, Gary, Rudick, Richard A, de Moor, Carl, Singh, Carol M, Fisher, Elizabeth, Koster, Thijs, Lublin, Fred D, Wolinsky, Jerry S, McFarland, Henry, Jacobson, Steven, Naylor, Maria L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150429/
https://www.ncbi.nlm.nih.gov/pubmed/37139460
http://dx.doi.org/10.1177/20552173231169463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150429/
https://www.ncbi.nlm.nih.gov/pubmed/37139460
http://dx.doi.org/10.1177/20552173231169463

Ejemplares similares